|
1
|
Riva L, Luzi L and Pelicci PG: Genomics of
acute myeloid leukemia: the next generation. Front Oncol. 2:402012.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Marcucci G, Maharry K, Radmacher MD,
Mrozek K, Vukosavljevic T, Paschka P, Whitman SP, Langer C, Baldus
CD, Liu CG, Ruppert AS, Powell BL, Carroll AJ, Caligiuri MA, Kolitz
JE, Larson RA and Bloomfield CD: Prognostic significance of, and
gene and microRNA expression signatures associated with, CEBPA
mutations in cytogenetically normal acute myeloid leukemia with
high-risk molecular features: a Cancer and Leukemia Group B Study.
J Clin Oncol. 26:5078–5087. 2008. View Article : Google Scholar
|
|
3
|
Schlenk RF, Döhner K, Krauter J, Frohling
S, Corbacioglu A, Bullinger L, Habdank M, Spath D, Morgan M, Benner
A, Schlegelberger B, Heil G, Ganser A and Döhner H; German-Austrian
Acute Myeloid Leukemia Study Group. Mutations and treatment outcome
in cytogenetically normal acute myeloid leukemia. New Engl J Med.
358:1909–1918. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Birg F, Courcoul M, Rosnet O, Bardin F,
Pebusque MJ, Marchetto S, Tabilio A, Mannoni P and Birnbaum D:
Expression of the FMS/KIT-like gene FLT3 in human acute leukemias
of the myeloid and lymphoid lineages. Blood. 80:2584–2593.
1992.PubMed/NCBI
|
|
5
|
Cairoli R, Beghini A, Grillo G, Nadali G,
Elice F, Ripamonti CB, Colapietro P, Nichelatti M, Pezzetti L,
Lunghi M, Cuneo A, Viola A, Ferrara F, Lazzarino M, Rodeghiero F,
Pizzolo G, Larizza L and Morra E: Prognostic impact of c-KIT
mutations in core binding factor leukemias: an Italian
retrospective study. Blood. 107:3463–3468. 2006.PubMed/NCBI
|
|
6
|
Gale RE, Hills R, Kottaridis PD, Srirangan
S, Wheatley K, Burnett AK and Linch DC: No evidence that FLT3
status should be considered as an indicator for transplantation in
acute myeloid leukemia (AML): an analysis of 1135 patients,
excluding acute promyelocytic leukemia, from the UK MRC AML10 and
12 trials. Blood. 106:3658–3665. 2005. View Article : Google Scholar
|
|
7
|
Ommen HB, Nyvold CG, Braendstrup K,
Andersen BL, Ommen IB, Hasle H, Hokland P and Ostergaard M: Relapse
prediction in acute myeloid leukaemia patients in complete
remission using WT1 as a molecular marker: development of a
mathematical model to predict time from molecular to clinical
relapse and define optimal sampling intervals. Br J Haematol.
141:782–791. 2008. View Article : Google Scholar
|
|
8
|
Dohner H, Estey EH, Amadori S, Appelbaum
FR, Büchner T, Burnett AK, Dombret H, Fenaux P, Grimwade D, Larson
RA, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz MA,
Sierra J, Tallman MS, Löwenberg B and Bloomfield CD; European
LeukemiaNet. Diagnosis and management of acute myeloid leukemia in
adults: recommendations from an international expert panel, on
behalf of the European LeukemiaNet. Blood. 115:453–474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
O'Donnell MR, Abboud CN, Altman J,
Appelbaum FR, Arber DA, Attar E, Borate U, Coutre SE, Damon LE,
Goorha S, Lancet J, Maness LJ, Marcucci G, Millenson MM, Moore JO,
Ravandi F, Shami PJ, Smith BD, Stone RM, Strickland SA, Tallman MS,
Wang ES, Naganuma M and Gregory KM: Acute myeloid leukemia. J Natl
Compr Cancer Netw. 10:984–1021. 2012.
|
|
10
|
Karp JE, Flatten K, Feldman EJ, Greer JM,
Loegering DA, Ricklis RM, Morris LE, Ritchie E, Smith BD, Ironside
V, Talbott T, Roboz G, Le SB, Meng XW, Schneider PA, Dai NT, Adjei
AA, Gore SD, Levis MJ, Wright JJ, Garrett-Mayer E and Kaufmann SH:
Active oral regimen for elderly adults with newly diagnosed acute
myelogenous leukemia: a preclinical and phase 1 trial of the
farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra)
combined with etoposide. Blood. 11:4841–4852. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tazzari PL, Tabellini G, Ricci F, Papa V,
Bortul R, Chiarini F, Evangelisti C, Martinelli G, Bontadini A,
Cocco L, McCubrey JA and Martelli AM: Synergistic proapoptotic
activity of recombinant TRAIL plus the Akt inhibitor perifosine in
acute myelogenous leukemia cells. Cancer Res. 68:9394–9403. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Moore J, Seiter K, Kolitz J, Stock W,
Giles F, Kalaycio M, Zenk D and Marcucci G: A Phase II study of
Bcl-2 antisense (oblimersen sodium) combined with gemtuzumab
ozogamicin in older patients with acute myeloid leukemia in first
relapse. Leuk Res. 30:777–783. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Furukawa Y, Vu HA, Akutsu M, Odgerel T,
Izumi T, Tsunoda S, Matsuo Y, Kirito K, Sato Y, Mano H and Kano Y:
Divergent cytotoxic effects of PKC412 in combination with
conventional antileukemic agents in FLT3 mutation-positive versus
-negative leukemia cell lines. Leukemia. 21:1005–1014. 2007.
|
|
14
|
Zhang YW, Wang SY, Lin X and Wang CY:
Identification of differentially expressed genes in familial acute
myelogenous leukemia by suppression subtractive hybridization.
Zhonghua Yi Xue Za Zhi. 87:533–537. 2007.(In Chinese).
|
|
15
|
Wang CY, Wang SY, Lin X, Zhang YW and Li
JG: Full-length cloning of a novel gene, ELF2C, related to familial
acute myelo-genous leukemia. Zhonghua Yi Xue Za Zhi. 87:2245–2248.
2007.(In Chinese).
|
|
16
|
Li JG, Wang SY, Huang YM and Wang CY:
Full-length cDNA cloning and biological function analysis of a
novel gene FAMLF related to familial acute myelogenous leukemia.
Zhonghua Yi Xue Za Zhi. 88:2667–2671. 2008.(In Chinese).
|
|
17
|
Hahn CN, Chong CE, Carmichael CL, Wilkins
EJ, Brautigan PJ, Li XC, Babic M, Lin M, Carmagnac A, Lee YK, Kok
CH, Gagliardi L, Friend KL, Ekert PG, Butcher CM, Brown AL, Lewis
ID, To LB, Timms AE, Storek J, Moore S, Altree M, Escher R, Bardy
PG, Suthers GK, D'Andrea RJ, Horwitz MS and Scott HS: Heritable
GATA2 mutations associated with familial myelodysplastic syndrome
and acute myeloid leukemia. Nat Genet. 43:1012–1017. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Holme H, Hossain U, Kirwan M, Walne A,
Vulliamy T and Dokal I: Marked genetic heterogeneity in familial
myelodysplasia/acute myeloid leukaemia. Br J Haematol. 158:242–248.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Preudhomme C, Renneville A, Bourdon V,
Philippe N, Roche-Lestienne C, Boissel N, Dhedin N, André JM,
Cornillet-Lefebvre P, Baruchel A, Mozziconacci MJ and Sobol H: High
frequency of RUNX1 biallelic alteration in acute myeloid leukemia
secondary to familial platelet disorder. Blood. 113:5583–5587.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Renneville A, Mialou V, Philippe N,
Kagialis-Girard S, Biggio V, Zabot MT, Thomas X, Bertrand Y and
Preudhomme C: Another pedigree with familial acute myeloid leukemia
and germline CEBPA mutation. Leukemia. 23:804–806. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ripperger T, Steinemann D, Göhring G,
Finke J, Niemeyer CM, Strahm B and Schlegelberger B: A novel
pedigree with heterozygous germline RUNX1 mutation causing familial
MDS-related AML: can these families serve as a multistep model for
leukemic transformation? Leukemia. 23:1364–1366. 2009. View Article : Google Scholar
|
|
22
|
Stelljes M, Corbacioglu A, Schlenk RF,
Döhner K, Frühwald MC, Rossig C, Ehlert K, Silling G, Müller-Tidow
C, Juergens H, Döhner H, Berdel WE, Kienast J and Koschmieder S:
Allogeneic stem cell transplant to eliminate germline mutations in
the gene for CCAAT-enhancer-binding protein α from hematopoietic
cells in a family with AML. Leukemia. 25:1209–1210. 2011.PubMed/NCBI
|
